1. Scrip
  2. >>Business

Turbulence Ahead For Indian Firms Caught In Russia-Ukraine Conflict

Dr Reddy's, Sun, Glenmark Have Interests In Region

 
• By Anju Ghangurde

Leading Indian firms with operations in the war zone stare at uncertainties and disruptions as sanctions by the US and Western allies threaten to choke the Russian economy.

russia ukraine
Indian Firms Caught In Russia-Ukraine Crossfire • Source: Alamy

As the US and West impose tough sanctions on Russia following its military operations in Ukraine, Indian drug makers with significant exposure in the region may have to brace for some tricky and difficult times ahead.

Front-line Indian firms such as Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Glenmark Pharmaceuticals Limited are among those with significant activity in the Russia-Commonwealth of Independent States CIS) region and immediate concerns could include the impact of the sharp depreciation of the Russian ruble and supply chain disruptions, though employee safety is undoubtedly the top priority for industry

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.